このエントリーをはてなブックマークに追加
ID 50635
FullText URL
Author
Mizote, Yu
Taniguchi, Taku
Tanaka, Kei
Isobe, Midori
Wada, Hisashi
Saika, Takashi
Kita, Shoichi
Koide, Yukari
Uenaka, Akiko
Nakayama, Eiichi
Abstract
Three novel NY-ESO-1 CD4 T cell epitopes were identified using PBMC obtained from patients who were vaccinated with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1). The restriction molecules were determined by antibody blocking and using various EBV-B cells with different HLA alleles as APC to present peptides to CD4 T cells. The minimal epitope peptides were determined using various N- and C-termini truncated peptides deduced from 18-mer overlapping peptides originally identified for recognition. Those epitopes were DRB1*0901-restricted NY-ESO-1 87-100. DQB1*0401-restricted NY-ESO-1 95-107 and DRB1*0803-restricted NY-ESO-1 124-134. CD4 T cells used to determine those epitope peptides recognized EBV-B cells or DC that were treated with recombinant NY-ESO-1 protein or NY-ESO-1-expressing tumor cell lysate, suggesting that the epitope peptides are naturally processed. These CD4 T cells showed a cytokine profile with Th1 characteristics. Furthermore, NY-ESO-1 87-100 peptide/HLA-DRB1*0901 tetramer staining was observed. Multiple Th1-type CD4 T cell responses are beneficial for inducing effective anti-tumor responses after NY-ESO-1 protein vaccination.
Published Date
2010-07-19
Publication Title
Vaccine
Volume
volume28
Issue
issue32
Publisher
Elsevier Sci Ltd
Start Page
5338
End Page
5346
ISSN
0264-410X
Content Type
Journal Article
Official Url
http://dx.doi.org/10.1016/j.vaccine.2010.05.044
Related Url
http://ousar.lib.okayama-u.ac.jp/metadata/50954
language
英語
Copyright Holders
(C) 2010 Elsevier Ltd. All rights reserved.
File Version
author
Refereed
True
DOI
Web of Sience KeyUT